Clinical trial
Levosimendan for Reducing Veno-arterial ECMO Weaning Failure During Refractory Cardiogenic Shock: a Retrospective Propensity Score Analysis
NCT04323709 is registered in ClinicalTrials.gov with Hospices Civils de Lyon as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Levosimendan for Reducing Veno-arterial ECMO Weaning Failure During Refractory Cardiogenic Shock: a Retrospective Propensity Score Analysis
- Lead sponsor
- Hospices Civils de Lyon
- Phase
- Observational
- Overall status
- Completed
- Start date
- January 1, 2019
- Completion date
- March 1, 2020
- Enrollment
- 200 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
cardiogenic shock, refractory shock